HEALTH CARE UTILIZATION AND COSTS AFTER WARFARIN DISCONTINUATION AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Wang, J. [1 ]
Qiao, Y. [1 ]
Spivey, C. A. [1 ]
Liu, X. [2 ]
Phatak, H. [3 ]
Mardekian, J. [4 ]
Claflin, A. B. [4 ]
Kachroo, S. [3 ]
Abdulsatter, Y. [4 ]
Parker, R. B. [1 ]
机构：
[1] Univ Tennessee, Coll Pharm, Memphis, TN USA
[2] Univ Tennessee, Coll Pharm, New York, NY USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.230
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV4
引用
收藏
页码：A756 / A756
页数：1
相关论文
共 50 条
  • [41] Total Healthcare Costs Before and After Stroke in Non-Valvular Atrial Fibrillation (NVAF) Patients Who Initiated Treatment With Rivaroxaban or Warfarin
    Lin, Jennifer H.
    Milentijevic, Dejan
    Shrivastava, Shubham
    Kogan, Emily
    Sjoeland, Erik
    Alberts, Mark
    [J]. STROKE, 2020, 51
  • [42] COMPARISON OF MORTALITY, HEALTH CARE UTILITY AND COST OF PATIENTS WITH WARFARIN TREATMENT FOR NON-VALVULAR ATRIAL FIBRILLATION VERSUS PATIENTS WITH OTHER TREATMENT
    Wang, L.
    Baser, O.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A340 - A340
  • [43] Reasons for discontinuation of direct oral anticoagulant therapy in patients with non-valvular atrial fibrillation
    Renner, Elizabeth
    Mouland, Erin
    Saad, Samira
    Ha, Nghi
    Kim, Pauline
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 617 - 618
  • [44] NON PHARMACOLOGICAL COMPARISON OF APIXABAN VERSUS WARFARIN IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Vargas Zea, N.
    Prieto Martinez, V
    Garrido Lecca, S.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A113 - A113
  • [45] Risk of ischemic stroke associated with DOAC discontinuation on patients with non-valvular atrial fibrillation
    Tlvaro Thomsen, Tobias
    Mesa Guadalupe, Jorge
    Cea Soriano, Lucia
    Huerta, Consuelo
    De Burgos, Airam
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 75 - 75
  • [46] Ischemic Stroke and Bleeding Risk in Patients with Non-valvular Atrial Fibrillation Treated with Warfarin
    He, S. B.
    Yu, S. H.
    Meng, R.
    Ru, S. W.
    Gong, Z. J.
    Liu, H. M.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S406 - S406
  • [47] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    [J]. CIRCULATION, 2014, 130
  • [48] Assessing the Clinical Characteristics of Non-Valvular Atrial Fibrillation Patients Who are Uncontrolled on Warfarin
    Lowenkopf, Theodore
    Stuchiner, Tamela
    Corless, Leslie
    Hartaigh, Briain O.
    Baraban, Elizabeth
    [J]. NEUROLOGY, 2021, 96 (15)
  • [49] A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation
    Pengo, Vittorio
    Zambon, Carlo-Federico
    Fogar, Paola
    Padoan, Andrea
    Nante, Giovanni
    Pelloso, Michela
    Moz, Stefania
    Frigo, Anna Chiara
    Groppa, Francesca
    Bozzato, Dania
    Tiso, Enrico
    Gnatta, Elisa
    Denas, Gentian
    Jose, Seena Padayattil
    Padrini, Roberto
    Basso, Daniela
    Plebani, Mario
    [J]. PLOS ONE, 2015, 10 (12):
  • [50] HEALTHCARE COSTS ASSOCIATED WITH NON-VALVULAR ATRIAL FIBRILLATION IN ITALY
    Cammarota, S.
    Citarella, A.
    Creazzola, S.
    De Marino, C.
    Izzo, P.
    La Bella, G.
    Piscitelli, R.
    Romagnuolo, F.
    Esposito, E.
    Guida, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A386 - A386
12345